Inhibikase Therapeutics (NYSE:IKT) Stock Price Down 3.2%

Inhibikase Therapeutics, Inc. (NYSE:IKTGet Free Report)’s stock price traded down 3.2% during mid-day trading on Thursday . The company traded as low as $1.52 and last traded at $1.53. 8,052 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 104,961 shares. The stock had previously closed at $1.58.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their price target on shares of Inhibikase Therapeutics from $27.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, May 21st.

Get Our Latest Stock Analysis on IKT

Inhibikase Therapeutics Trading Down 3.2 %

The company has a market cap of $11.04 million, a price-to-earnings ratio of -0.46 and a beta of 1.41. The firm has a 50-day moving average price of $1.75 and a 200 day moving average price of $1.86.

Inhibikase Therapeutics (NYSE:IKTGet Free Report) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.06. Inhibikase Therapeutics had a negative net margin of 5,886.15% and a negative return on equity of 147.03%. Research analysts anticipate that Inhibikase Therapeutics, Inc. will post -1.87 earnings per share for the current fiscal year.

About Inhibikase Therapeutics

(Get Free Report)

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.

Further Reading

Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with's FREE daily email newsletter.